Conclusion
Author:
- 6 November 2013
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 9 (sup12) , 41
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Updated Overall Survival Analysis in Oceans, a Randomized Phase 3 Trial of Gemcitabine (G) + Carboplatin (C) and Bevacizumab (BV) or Placebo (PL) Followed by BV or PL in Platinum-Sensitive Recurrent Epithelial Ovarian (ROC), Primary Peritoneal (PPC), or Fallopian Tube Cancer (FTC)Annals of Oncology, 2012
- Independent radiologic review of OCEANS, a phase III trial of carboplatin, gemcitabine, and bevacizumab or placebo for the treatment of platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerGynecologic Oncology, 2012
- Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical CancerJournal of Clinical Oncology, 2011